Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bioceltix S.a. (BCX.WA)
PLN92.00
+0.00 (+0.00%)
PL WSE Healthcare Biotechnology
Address
Building III 51-317
Wroclaw, DS, PL
Wroclaw, DS, PL
CEO
Lukasz Piotr Bzdzion
Website
bioceltix.com
IPO
2021-11-08
ISIN PLBCLTX00019
Description
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company’s products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wroclaw, Poland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
PLN92.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6.5K
Beta
0.91
Float Shares
4.06M
Free Float %
73.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.61% | +0.37% | -6.70% | +1.36% | -8.57% | +1.99% | -20.91% | +16.95% | +134.57% | +134.57% | +134.57% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
92.00
DCF (Unlevered)
14.01
-84.8%
DCF (Levered)
13.62
-85.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
115.81
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+7.6% Q1'26: -33.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-333.7% Q1'26: -349.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+10.2% Q1'26: +12.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
|
—
|
43.00M
43.00M – 43.00M
|
27.00M
27.00M – 27.00M
-37.2% YoY
|
43.00M
43.00M – 43.00M
+59.3% YoY
|
| EBITDA |
-14.04M
|
-16.64M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-14.61M
|
-17.32M
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-14.90M
est: -14.52M (-2.6%)
|
-15.16M
est: -16.50M (+8.1%)
|
67.48M
67.48M – 67.48M
+509.1% YoY
|
4.50M
4.50M – 4.50M
-93.3% YoY
|
9.00M
9.00M – 9.00M
+100.0% YoY
|
| SGA |
11.81M
|
12.97M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.28
est: -3.20 (-2.5%)
|
-3.03
est: -3.30 (+8.2%)
|
13.50
13.50 – 13.50
+509.1% YoY
|
0.90
0.90 – 0.90
-93.3% YoY
|
1.80
1.80 – 1.80
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-12.00M
OE per share TTM
-2.38
Owner's Yield
-2.77%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
102,119.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 61.3K | 0.65% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
5.53M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lukasz Bzdzion | CEO & President of the Management Board | 522.3K | male |
| Pawel Wielgus | Member of the Management Board | 522.3K | male |
| Anna Olko-Chudy | Head of the Management Office & Tissue Coordinator | — | female |
| Grzegorz Ostropolski | Chief Operating Officer | — | male |
| Jakub Wacek | Legal Counsel & General Counsel | — | male |
| Agnieszka Kielczykowska | Head of Procurement & Supply | — | female |
| Lahoud Touma | Director of Technology | — | male |
| Patryk Reniewicz | Head of R&D and Leader of the In Vitro Diagnostics Development Team | — | — |
| Katarzyna Wroblewska | Head of Quality Assurance | — | female |
| Andrij Wlach | Chief Financial Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BCX.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
